

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-17. (Canceled)

18. (Currently Amended) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants and a second component selected from the group consisting of monoclonal antibodies and antigen-binding fragments thereof that specifically bind to amino acid residues 120-139, 151-169 or 165-184 of SEQ ID NO: 114.

19.-20. (Canceled)

21. (Previously Presented) An isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to amino acid residues 120-139, 151-169 or 165-184 of SEQ ID NO: 114.

22. (Previously Presented) The composition of claim 18, wherein the composition is effective for inhibiting tumor growth.